Actively Recruiting
A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE
Led by Hospices Civils de Lyon · Updated on 2021-07-27
2000
Participants Needed
5
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The number of patients affected by cancer and treated with immunotherapy is continuously increasing. With the advent of these new therapies, the investigators observe the emergence of new and unexpected toxicities. The care of patients treated with these molecules require the development of multidisciplinary skills and the introduction of a professional network capable of taking care of immunotherapy related toxicity (irAE) that can affect different organs and for which immediate and effective interventions are necessary for patient survival. IMMUCARE-BASE will comprehensively enable the collection, of clinical and biological data of patients treated with anticancer immunotherapy. The creation of this database is essential to identify clinico-biological factors predisposing to toxicity, and to define the best strategies to prevent the early onset of irAE and/or to treat them. Ultimately, the objective of this database is to collect enough data to be able to personalise in the future the immunotherapy treatment according to the benefits and to anticipate risks for each patient. The objective of the biological collection is to perform ancillary studies for understanding mechanism leading to toxicity and for the development of research programs in the field of immunotherapy.
CONDITIONS
Official Title
A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18
- Starting anticancer immunotherapy treatment (including immune checkpoint inhibitors like anti-PD-1, anti-PD-L1, anti-CTLA4, anti-Lag-3, anti-Tim-3, anti-TIGIT) alone or with other anticancer drugs
- Previous immunotherapy must have been more than 6 months ago to be eligible
- Received written information about IMMUCARE-BASE
- Patients in clinical trials may be eligible if allowed by the trial's promoter
- Patients in blinded clinical trials may participate if immunotherapy is not blinded and concomitant participation is allowed
- Patients who stopped prior IMMUCARE-BASE participation due to treatment change can rejoin if new immunotherapy starts after 6 months from last treatment
- Signed informed consent for biological sample collection
You will not qualify if you...
- Received immunotherapy within 6 months before joining IMMUCARE-BASE
- Under 18 years old
- Pregnant women
- Under legal protection
- Refused to participate
- Weight 50 kg or less for biological collection
- Hemoglobin less than 90 g/L at inclusion
- Participating in clinical trials with blood samples taken for ancillary studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Hôpital L. Pradel
Bron, France
Not Yet Recruiting
2
Hôpital Pierre Wertheimer
Bron, France
Not Yet Recruiting
3
Hôpital de la Croix Rousse
Lyon, France
Not Yet Recruiting
4
Hôpital E Herriot
Lyon, France
Not Yet Recruiting
5
Centre Hospitalier LYON SUD
Pierre-Bénite, France
Actively Recruiting
Research Team
J
Jonathan LOPEZ, MD
CONTACT
S
Sara CALATTINI, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here